XENETIC BIOSCIENCES INC

XBIO is the ticker symbol for Xenetic Biosciences, Inc., a biopharmaceutical company traded on the Nasdaq Capital Market. The stock represents ownership in a clinical-stage company focused on developing immune-oncology therapies and targeted biologic medicines. Because XBIO is a small-cap, clinical-stage biotech, its share price can be sensitive to pipeline updates and financing news. For current price and market capitalization, check the latest XBIO data displayed on this page.

Recent performance for XBIO is best measured using the latest market data shown on this page, as prices move daily. Key reference points include the 52-week high and low, year-to-date return, and average trading volume. As a micro-cap biotech, XBIO can experience sharp moves around clinical milestones, financing activities, or broader sector sentiment, so reviewing the most recent chart and performance statistics is important.

Valuation for XBIO is not easily captured by traditional P/E ratios because clinical-stage biotechs often have minimal or no product revenue. Investors typically review cash position, pipeline stage, addressable market, and comparable company valuations. For the latest market capitalization and any available valuation multiples, refer to the current XBIO data displayed on this page rather than relying on fixed figures.

XBIO can be bought through a brokerage account that offers Nasdaq-listed securities. Most online brokers allow you to place a market or limit order during regular trading hours. Before trading, confirm whether your broker charges commissions, whether fractional shares are supported, and what order types are available. The execution price will reflect the current market quote for XBIO at the time your order fills.

Analyzing XBIO's financial performance involves reviewing its quarterly and annual reports for cash and cash equivalents, operating expenses, research and development spending, and net loss. Because XBIO is clinical-stage, revenue may be limited or irregular, so cash runway and financing needs are often more informative than earnings. These documents are available through SEC filings and the company's investor relations page.

XBIO carries risks common to clinical-stage biotechs, including pipeline failure, regulatory delays, and the need to raise additional capital, which can dilute existing shareholders. As a small-cap stock, XBIO may also have lower liquidity and higher price volatility than larger companies. Broader market and sector downturns can amplify these risks. Reviewing SEC filings and company disclosures can help investors understand specific risk factors.